Notification of Full Year Results

RNS Number : 6444B

Alliance Pharma PLC

15 February 2022

 

For immediate release

15 February 2022

ALLIANCE PHARMA PLC

("Alliance" or the "Group")

Notification of Full Year Results,

Analyst Meeting and Webcast

Alliance Pharma plc (AIM: APH), the international healthcare group, will announce its results for the year ended 31 December 2021 on Tuesday 22 March 2022.

A meeting for analysts will be held at 9.30am on the day of the results at Investec Bank plc, 30 Gresham Street, London EC2V 7QP. To register for the meeting, analysts should contact Buchanan at [e-mail] .

A live webcast of the analyst meeting will be accessible via the following link: https://webcasting.buchanan.uk.com/broadcast/620a757b26d01a4c0553d15f .

A recording of the webcast will be made available following the meeting at the investor section of Alliance's website, https://www.alliancepharmaceuticals.com/investors .

For further information:

Alliance Pharma plc	+ 44 (0)1249 466966
Head of Investor Relations: Cora McCallum
[e-mail] www.alliancepharma.co.uk
Buchanan	+ 44 (0)20 7466 5000
Mark Court / Sophie Wills / Hannah Ratcliff
[e-mail]
Numis Securities Limited	+ 44 (0)20 7260 1000
Nominated Adviser: Freddie Barnfield / Duncan Monteith
Corporate Broking: James Black

Investec Bank plc	+ 44 (0) 20 7597 5970
Corporate Finance: Daniel Adams
Corporate Broking: Patrick Robb

About Alliance

Alliance Pharma plc (AIM: APH) is an international healthcare group. Our purpose is to improve the lives of consumers and patients through making available a range of clinically valuable healthcare products.

Our core focus is on the marketing of Consumer Healthcare brands, complemented by a smaller Prescription Medicines business. In total, we hold marketing rights to around 80 brands, with revenues generated from a mix of direct, distributor and e-commerce sales.

Headquartered in the UK, the Group employs around 250 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics operations, we remain asset-light and focused on maximising the value of our brands.

For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com

 

END

 

 

NORSFIFWLEESESE